Placeholder Banner

BIO Submits Comments to FDA on Enhancing Patient Engagement Efforts

June 12, 2017

 

BIO submitted comments to the Food and Drug Administration (FDA) on Enhancing Patient Engagement Efforts Across the Food and Drug Administration.

BIO applauds the FDA for its commitment to integrating patient perspectives into drug development and regulatory review processes. BIO also supports FDA’s proposed Office of Patient Affairs (OPA) to provide a more transparent, accessible, and positive experience for patient communities.

BIO agrees the proposed OPA could receive inquiries about and better coordinate patient-focused activities across the Agency, as well as play a transformative role in developing a forward-looking platform enabling patients and the scientific community to more easily obtain information about patient-focused drug development activities. OPA could also serve as a valuable resource for patients, patient advocacy organizations, and the larger scientific community.

BIO says OPA should ensure timely communication and transparency with sponsors by informing them how to incorporate patient perspective data into an Investigational New Drug Application (IND) and Marketing Application. Additionally, OPA should support and coordinate with pharmaceutical sponsors seeking to include the patient voice in drug development as well as benefit-risk assessments.

BIO provides additional recommendations on OPA governance, data management systems, and other clarifications.

Download Full Comments Below
BIO Letter PatientEngagement - 6-12-17 - FINAL
Read full comment letter below
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
The Biotechnology Innovation Organization (BIO) is pleased to respond to the U.S. Department of Agriculture’s (USDA) Solicitation of Input from Stakeholders on Agricultural Innovations. BIO applauds USDA for taking a proactive approach and seeking…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…